Prophylactic Use of Tranexamic Acid for Reduction of Blood Loss during and after Primary Cesarean Section Randomized Controlled Trial

Abstract

Obstetric hemorrhage is the leading cause of maternal morbidity and mortality. Caesarean section (CS) rates have increased to 25 to 30 % in many areas of the world. In order to reduce maternal mortality and morbidity caused by bleeding, it is important to reduce the amount of bleeding during and after lower segment caesarean section (LSCS). Tranexamic acid is a synthetic derivative of the amino acid lysine that exerts its antifibrinolytic effect through the reversible blockade of the lysine binding sites on plasminogen molecules. Also TXA may enhance the effectiveness of patient’s own hemostatic mechanism.